Plain-English translation of NCT02089685 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Kidney cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial studied whether , a type of immunotherapy drug, worked better when combined with other cancer medications in people with advanced melanoma (skin cancer) or advanced kidney cancer. Researchers tested three different combination approaches to see which were safest and most effective, and they looked at different dosing schedules to find the best way to give these treatments.
Advanced melanoma and kidney cancer are serious diseases that often don't respond well to standard treatments. This medication works by helping the immune system fight cancer cells, and researchers wanted to see if combining it with other immune-boosting drugs could improve results for patients with these difficult-to-treat cancers.
Participants received intravenous infusions of every three weeks, combined with either a weekly injection of pegylated interferon or periodic infusions of (another immunotherapy), depending on which arm of the study they were in. The trial involved multiple visits to the clinic for infusions, blood work, and imaging scans to monitor how the cancer responded and how well the participant tolerated the treatment. Most participants continued treatment for up to about 2 years, though some had the option to receive additional treatment if their cancer progressed after an initial course.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice